Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?

Zhang, Xiaoyun; Xu, Shuo; Wang, Jiaqi; Lv, Yalei; Wang, Na; Lai, Ruixue; Sha, Ziyue; Zhao, Qun; Guo, Zhanjun

doi:10.1186/s12885-022-10199-x

Cited by 4 publications

(3 citation statements)

References 33 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have suggested a potential association between irAEs and a more favorable response to immunotherapy in patients [118,119]. Additionally, research has demonstrated a correlation between the occurrence of irAEs following immunotherapy and improved survival outcomes in GC patients [120][121][122]. Furthermore, certain studies have identified potential biomarkers for predicting the occurrence of irAEs [123].…”

Section: Predictive Biomarkers Of Immunotherapy-related Adverse Event...mentioning

confidence: 99%

Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects

Hou,

Zhao,

Zhu

2023

IJMS

View full text Add to dashboard Cite

Gastric cancer presents substantial management challenges, and the advent of immunotherapy has ignited renewed hope among patients. Nevertheless, a significant proportion of patients do not respond to immunotherapy, and adverse events associated with immunotherapy also occur on occasion, underscoring the imperative to identify suitable candidates for treatment. Several biomarkers, including programmed death ligand-1 expression, tumor mutation burden, mismatch repair status, Epstein–Barr Virus infection, circulating tumor DNA, and tumor-infiltrating lymphocytes, have demonstrated potential in predicting the effectiveness of immunotherapy in gastric cancer. However, the quest for the optimal predictive biomarker for gastric cancer immunotherapy remains challenging, as each biomarker carries its own limitations. Recently, multi-omics technologies have emerged as promising platforms for discovering novel biomarkers that may help in selecting gastric cancer patients likely to respond to immunotherapy. The identification of reliable predictive biomarkers for immunotherapy in gastric cancer holds the promise of enhancing patient selection and improving treatment outcomes. In this review, we aim to provide an overview of clinically established biomarkers of immunotherapy in gastric cancer. Additionally, we introduce newly reported biomarkers based on multi-omics studies in the context of gastric cancer immunotherapy, thereby contributing to the ongoing efforts to refine patient stratification and treatment strategies.

show abstract

Section: Predictive Biomarkers Of Immunotherapy-related Adverse Event...mentioning

confidence: 99%

Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects

Hou,

Zhao,

Zhu

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…irAEs that occur early after treatment initiation are associated with favorable PFS and ORR in NSCLC patients treated with nivolumab [ 150 ]. Patients with gastric adenocarcinoma with irAEs treated with anti-PD-1 antibodies had a longer OS (176 days vs 94 days, P ═ 0.001) than patients without irAEs, and the occurrence of irAEs was an independent favorable prognostic factor in this group [ 152 ].…”

Section: Advances In Predictive Biomarkersmentioning

confidence: 99%

Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy - a review

Zdrenka,

Kowalewski,

Ahmadi

et al. 2023

Biomol Biomed

View full text Add to dashboard Cite

Anti-programmed cell death ligand 1 (Anti-PD-L1) immunotherapy is an increasingly crucial in cancer treatment. To date, the Federal Drug Administration has approved four PD-L1 immunohistochemistry (IHC) staining protocols, commercially available in the form of "kits", facilitating testing for PD-L1 expression. These kits comprise four PD-L1 antibodies on two separate IHC platforms, each utilizing distinct, non-interchangeable scoring systems. Several factors, including tumor heterogeneity and the size of the tissue specimens assessed, can lead to PD-L1 status misclassification, potentially hindering the initiation of therapy. Therefore, the development of more accurate predictive biomarkers to distinguish between responders and non-responders prior to anti-PD-1/PD-L1 therapy warrants further research. Achieving this goal necessitates refining sampling criteria, enhancing current methods of PD-L1 detection, and deepening our understanding of the impact of additional biomarkers. In this article, we review potential solutions to improve the predictive accuracy of PD-L1 assessment in order to more precisely anticipate patients' responses to anti-PD-1/PD-L1 therapy, monitor disease progression and predict clinical outcomes.

show abstract

“…IrAEs have been proven to promote the treatment e cacy of ICIs in patients with melanoma, NSCLC, hepatocellular carcinoma, and gastric cancer (Nakamura et al, 2017;Toi et al, 2018;Xu et al, 2021;Zhang et al, 2022). However, the relationship between irAE-related AI and ICIs treatment e cacy has not yet been evaluate owing to the low incidence and concealment of AI.…”

Section: Introductionmentioning

confidence: 99%

Immune-related adverse event-related adrenal insufficiency mediates immune checkpoint inhibitors efficacy for cancer treatment

Zhang,

Wu,

Zhao

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose Immune checkpoint inhibitors (ICIs) have significantly improved the outcomes of patients with cancer. An increasing number of immune-related adverse events (irAEs) have been discovered with the widespread clinical application of ICIs, which appear to be associated with improved treatment efficacy in certain cancers. We aimed to evaluate the correlation between irAE-related adrenal insufficiency (AI) and ICI treatment efficacy. Methods Patients were divided into irAE-A (patients with irAE-related AI), irAE-B (patients with other irAEs) and non-irAE groups. Immunotherapy efficacy was assessed based on the disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Survival probabilities were estimated using the Kaplan–Meier method with the log–rank test. Results One hundred and ninety-two patients with cancer including gastrointestinal, respiratory, and other cancers, who received ICIs were enrolled in this study. The DCR of the irAE-A and irAE-B groups were higher than that of the non-irAE group (P < 0.05). Multiple extended Cox regression analyses showed that irAE status (irAE-A vs. non-irAE, P = 0.008; irAE-B vs. non-irAE, P = 0.020), ECOG status (P = 0.045), TNM stage (P = 0.000), and treatment line (P = 0.002) were independent predictors of PFS. Meanwhile, irAE status (irAE-A vs. non-irAE, P = 0.009; irAE-B vs. non-irAE, P = 0.013), ECOG status (P = 0.007), TNM stage (P = 0.035), treatment line (P = 0.001) and treatment modality (P = 0.008) were independent predictors for OS. Conclusions IrAE-related AI was significantly associated with better clinical outcomes in patients with cancer and is a potentially predictable marker for better ICI treatment efficacy.

show abstract

Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?

Cited by 4 publications

References 33 publications

Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects

Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects

Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy - a review

Immune-related adverse event-related adrenal insufficiency mediates immune checkpoint inhibitors efficacy for cancer treatment

Contact Info

Product

Resources

About